Sayan Sharma

Mr. Sayan Sharma

Department of Pathology, University of Otago, Dunedin, Otago, New Zealand
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Anti-Infective Agents
Verified
Journal Article
Closed access
PDF file
Sayan SharmaSayan Sharma
Sayan Sharma
PGPuja Ghosh
Puja Ghosh
CKChirantan Kar
Chirantan Kar
RGRajgourab Ghosh
Rajgourab Ghosh
Viral infections impact millions of individuals annually and in 2018, the WHO called for global preparedness to address potential high-mortality pathogens, referred to as "Pathogen X," which can include fungi, viruses, parasites, or prions. The constant evolution of RNA viruses leads to continually changing variants, challenging the effectiveness of vaccines and drugs. In underserved healthcare regions, plant-based phytochemicals offer promise in combating viral diseases due to their ready availability, proven effectiveness, and low toxicity. Amidst the evolving virus variants and recurring fatal outbreaks, especially in resource- constrained regions, phytochemicals hold promise as potential anti-infective agents. This review delves into plant-based antivirals, aiming to update plant-derived antiviral compounds' status against existing and emerging viruses from 2019 to 2023. The study aimed to identify active components from medicinal plants with IC50 and EC50 values against human- infecting viruses. It utilized in vitro and in vivo methods to predict phytochemical mechanisms and enhance bioavailability. Among the phytochemicals studied as antivirals, Emodin, Quercetin, Myricetin, Resveratrol, and Silymarin demonstrated efficacy against multiple viruses. Notably, certain plant compounds were effective against multiple viruses and could serve as potential antiviral treatments. Overall, the review illustrates that harnessing plant-derived compounds shows promise in combating current and evolving infectious threats.

Verified
Journal Article
Open access
PDF file
Sayan SharmaSayan Sharma
Sayan Sharma
Lynette HodgesLynette Hodges
Lynette Hodges
KPKatie Peppercorn
Katie Peppercorn
JDJemma Davis
Jemma Davis
CEChristina D. Edgar
Christina D. Edgar
WTWarren Perry Tate
Warren Perry Tate
Post-exertional malaise (PEM) is a defining symptom of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), yet its molecular underpinnings remain elusive. This study investigated the temporal–longitudinal DNA methylation changes associated with PEM using a structured two-day maximum repeated effort cardiopulmonary exercise testing (CPET) protocol involving pre- and two post-exercise blood samplings from five ME/CFS patients. Cardiopulmonary measurements revealed complex heterogeneous profiles among the patients compared to typical healthy controls, and VO2 peak indicated all patients had poor normative fitness. The switch to anaerobic metabolism occurred at a lower workload in some patients on Day Two of the test. Reduced Representation Bisulphite Sequencing followed by analysis with Differential Methylation Analysis Package-version 2 (DMAP2) identified differentially methylated fragments (DMFs) present in the DNA genomes of all five ME/CFS patients through the exercise test compared with ‘before exercise’. With further filtering for >10% methylation differences, there were early DMFs (0–24 h after first exercise test) and late DMFs between (24–48 h after the second exercise test), as well as DMFs that changed gradually (between 0 and 48 h). Of these, 98% were ME/CFS-specific, compared with the two healthy controls accompanying the longitudinal study. Principal component analysis illustrated the three distinct clusters at the 0 h, 24 h, and 48 h timepoints, but with heterogeneity among the patients within the clusters, highlighting dynamic methylation responses to exertion in individual patients. There were 24 ME/CFS-specific DMFs at gene promoter fragments that revealed distinct patterns of temporal methylation across the timepoints. Functional enrichment of ME-specific DMFs revealed pathways involved in endothelial function, morphogenesis, inflammation, and immune regulation. These findings uncovered temporally dynamic epigenetic changes in stress/immune functions in ME/CFS during PEM and suggest molecular signatures with potential for diagnosis and of mechanistic significance.

Verified
Journal Article
Open access
PDF file
KPKatie Peppercorn
Katie Peppercorn
Sayan SharmaSayan Sharma
Sayan Sharma
CEChristina D. Edgar
Christina D. Edgar
PSPeter Averill Stockwell
Peter Averill Stockwell
EREuan Rodger
Euan Rodger
WTWarren Perry Tate
Warren Perry Tate
Post-viral conditions, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID (LC), share > 95% of their symptoms, but the connection between disturbances in their underlying molecular biology is unclear. This study investigates DNA methylation patterns in peripheral blood mononuclear cells (PBMC) from patients with ME/CFS, LC, and healthy controls (HC). Reduced Representation Bisulphite Sequencing (RRBS) was applied to the DNA of age- and sex-matched cohorts: ME/CFS (n = 5), LC (n = 5), and HC (n = 5). The global DNA methylomes of the three cohorts were similar and spread equally across all chromosomes, except the sex chromosomes, but there were distinct minor changes in the exons of the disease cohorts towards more hypermethylation. A principal component analysis (PCA) analysing significant methylation changes (p < 0.05) separated the ME/CFS, LC, and HC cohorts into three distinct clusters. Analysis with a limit of >10% methylation difference and at p < 0.05 identified 214 Differentially Methylated Fragments (DMF) in ME/CFS, and 429 in LC compared to HC. Of these, 118 DMFs were common to both cohorts. Those in promoters and exons were mainly hypermethylated, with a minority hypomethylated. There were rarer examples with either no change in methylation in ME/CFS but a change in LC, or a methylation change in ME/CFS but in the opposite direction in LC. The differential methylation in a number of fragments was significantly greater in the LC cohort than in the ME/CFS cohort. Our data reveal a generally shared epigenetic makeup between ME/CFS and LC but with specific, distinct changes. Differences between the two cohorts likely reflect the stage of the disease from onset (LC 1 year vs. ME/CFS 12 years), but specific changes imposed by the SARS-CoV-2 virus in the case of the LC patients cannot be discounted. These findings provide a foundation for further studies with larger cohorts at the same disease stage and for functional analyses to establish clinical relevance.

1 December 2024 in Current Protein & Peptide Science
Verified
Journal Article
Closed access
PDF file
Sayan SharmaSayan Sharma
Sayan Sharma
OSOindrila Sarkar
Oindrila Sarkar
RGRajgourab Ghosh
Rajgourab Ghosh
: Unconventional Post-Translational Modifications (PTMs) have gained increasing attention as crucial players in cancer development and progression. Understanding the role of unconventional PTMs in cancer has the potential to revolutionize cancer diagnosis, prognosis, and therapeutic interventions. These modifications, which include O-GlcNAcylation, glutathionylation, crotonylation, including hundreds of others, have been implicated in the dysregulation of critical cellular processes and signaling pathways in cancer cells. This review paper aims to provide a comprehensive analysis of unconventional PTMs in cancer as diagnostic markers and therapeutic targets. The paper includes reviewing the current knowledge on the functional significance of various conventional and unconventional PTMs in cancer biology. Furthermore, the paper highlights the advancements in analytical techniques, such as biochemical analyses, mass spectrometry and bioinformatic tools etc., that have enabled the detection and characterization of unconventional PTMs in cancer. These techniques have contributed to the identification of specific PTMs associated with cancer subtypes. The potential use of Unconventional PTMs as biomarkers will further help in better diagnosis and aid in discovering potent therapeutics. The knowledge about the role of Unconventional PTMs in a vast and rapidly expanding field will help in detection and targeted therapy of cancer.

20 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
KPKatie Peppercorn
Katie Peppercorn
Sayan SharmaSayan Sharma
Sayan Sharma
CEChristina D Edgar
Christina D Edgar
PSPeter Averill Stockwell
Peter Averill Stockwell
EREuan Rodger
Euan Rodger
WTWarren Perry Tate
Warren Perry Tate
Post-viral conditions, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID (LC), share >95% of their symptoms, but the connection between disturbances in their underlying molecular biology is unclear. This study investigates DNA methylation patterns in peripheral blood mononuclear cells (PBMC) from patients with ME/CFS, LC, and healthy controls (HC). Reduced Representation Bisulphite Sequencing (RRBS) was applied to the DNA of age- and sex-matched cohorts: ME/CFS (n=5), LC (n=5) and HC (n=5). The global DNA methylomes of the three cohorts were similar and spread equally across all chromosomes, except the sex chromosomes, but there were distinct minor changes in the exons of the disease cohorts towards more hypermethylation. A principal component analysis (PCA) analysing significant methylation changes (p10% methylation difference and at P<0.05 identified 214 Differentially Methylated Fragments (DMF) in ME/CFS, and 429 in LC compared to HC. Of these 118 DMFs were common to both cohorts. Those in promoters and exons were mainly hypermethylated, with a minority hypomethylated. There were rarer examples with either no change in methylation in ME/CFS but a change in LC, or a methylation change in ME/CFS but in the opposite direction in LC. The differential methylation in a number fragments was significantly greater in the LC cohort than in the ME/CFS cohort. Our data reveal a generally shared epigenetic makeup between ME/CFS and LC but with specific distinct changes. Differences between the two cohorts likely reflect the stage of the disease from onset (LC 1 year vs ME/CFS 12 years) but specific changes imposed by the SARS-COV-2 virus in the case of the LC patients cannot be discounted. These findings provide a foundation for further studies with larger cohorts at the same disease stage and for functional analyses to establish clinical relevance.

1 January 2024 in Medical Research Archives
Verified
Journal Article
Open access
PDF file
WTWarren Perry Tate
Warren Perry Tate
KPKatie Peppercorn
Katie Peppercorn
BGBryn W.C Griffiths
Bryn W.C Griffiths
Sayan SharmaSayan Sharma
Sayan Sharma
The COVID-19 pandemic was unprecedented in the number of people affected from all cultures and countries. It posed immediate challenges of how to counter the Severe Acute Respiratory Syndrome-Coronovirus-2 that was causing fatalities, overburdening hospitals, and to develop effective vaccines and antivirals to complement the public health measures. The ribonucleic acid technology used to develop a novel class of vaccines proved highly successful in reducing the severe case numbers and fatalities. More challenging were the secondary long lasting effects from the viral infection in a relatively high proportion of patients now estimated to be in the range of 5-15%. The post viral condition, termed publicly Long COVID, and clinically Post Acute Sequelae of COVID-19 surprised many clinicians with its intractability. However, it mirrored previous experiences of patients suffering from ongoing post-viral (stressor) conditions, covered by the umbrella term, Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome. From over 775 million worldwide COVID-19 infections reported to date there has arisen an estimated 60 million cases of Long COVID. Long COVID is a hetergeneous condition with ~50% having a classic Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-like syndrome with over 200 similar symptoms to those reported for this syndrome, but in addition ~25% are debilitated following the specific acute effects of the virus on body organs like the lungs, heart, and kidneys. This heterogeneity highlights the challenges of developing future management strategies, and treatments for the group as a whole to at least lessen the burden for all, and to reverse the fatigue syndrome post-viral condition for those with that clinical phenotype. Opportunities to understand Long COVID as a model of post-viral conditions are possible because the condition has arisen with such a large number of cases specific from this single stressor at the same time. Meaningful longitudinal patient studies can now be initiated and its immediacy and frequency has caught the attention of clinicians and scientists worldwide. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome cases by contrast have arisen constantly as a ‘drip feed’ in small numbers from boutique infectious outbreaks like the first Severe Acute Respiratory Syndrome virus epidemic in 2003 where there were only ~ 9000 infections, or from endemic viruses like Epstein-Barr virus (glandular fever) from which ~5-10% develop a post-viral condition, but additionally from other major stressors. Widespread interest and investment in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome research has been lacking. Long COVID has now many talented scientists and clinicians researching its pathophysiology, and there has been significant investment, spearheaded in the United States through the ‘Recover Initiative’. It is hoped promising treatments can now be developed and tested in clinical trials. This gives hope for the ‘missing millions’ of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients worldwide, many of whom have had their condition neglected for decades. Beyond the core symptoms that define the clinical case definitions for both Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome it is becoming clear the broader symptoms of an individual patient can not only reflect their previous health histories and co-morbidities, but also their specific genetic background. The major challenge ahead is there will likely need an individual-focused treatment strategy to improve the quality of life for these patients. Fundamental advances are still needed like simple accessible diagnostic tests based on molecular markers that can rapidly confirm the condition, follow its progress, and identify those at risk.